Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announc ...
The poster presented data from AUTX-703, a potent, selective and orally bioavailable heterobifunctional degrader of KAT2A/B, an AURIGIN-identified histone acetyltransferase driving small cell lung ...
2d
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®, a new ...
Less than 24 hours ago, u/ChipsNoDip shared a screenshot of DNA test results captioned: "Thought it'd be fun to get a test, ...
News-Medical.Net on MSN2d
NUZ-001 shows positive results in human 3D brain modelNeurizon Therapeutics Limited (“Neurizon”), a clinical-stage biotech company dedicated to advancing treatments for ...
EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T ...
BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, ...
Xenon Pharmaceuticals Inc. , a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced ...
The upcoming Therapeutic Oligonucleotides 2025 conference, hosted by ELRIG, will take place at AstraZeneca’s R&D site in ...
MaaT Pharma To Present New Promising Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to ...
Secondary endpoints in the MINDFuL trial include the CDR-SB, E-Cog, ADL and Neuropsychiatric Inventory (NPI) instruments, ...
The PIK3CA wild-type cohort of the VIKTORIA-1 Phase 3 trial is on track to report topline data in Q2 2025VIKTORIA-2 Phase 3 remains on track to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback